Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL®, a ...

Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

The Food and Drug Administration approved obecabtagene autoleucel, or Aucatzyl from Autolus, a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or ...

The immune system and especially the B cells of patients with acute lymphoblastic leukemia (ALL) is severely compromised following withdrawal from therapy, according to a new study. However, 6 months ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia ... Radon, Even at Levels Below EPA Guideline for Mitigation, Is Linked to Childhood Leukemia ...

Sternal-marrow puncture showed a normal bone marrow, with only a slight increase of basophilic erythroblast ... Thus, each year 1 case of acute leukemia occurred among 20,000 people.